跳至主要内容
临床试验/NCT00841243
NCT00841243Unknown4 期

The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial

UMC Utrecht1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2009年3月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
发起方
UMC Utrecht
入组人数
50
试验地点
1
主要终点
Weight loss

研究概览

简要总结

Standard antiviral treatment consists of weekly injections with Peginterferon-α in combination with ribavirin. This treatment may lead to significant weight loss (7% within 24 weeks on average), with decreased quality of life. In this study the investigators will examine in 50 patients whether nutritional advise and support can prevent weight loss during antiviral therapy.

详细描述

Standard antiviral treatment consists of weekly injections with Peginterferon-α in combination with ribavirin. This therapy, however, leads to weight loss of approximately 7% in the first 24 weeks of therapy possibly related to impaired postprandial gastric emptying. Such rapid weight loss is a marker of deterioration of the nutritional status with increased risk of complications and reduced immunological barrier function. Deterioration of the nutritional status also exacerbates side effects of the antiviral treatment like fatigue and depression. As a result, the quality of life of these patients may decrease. In the current controlled, prospective, multicenter, study we primarily aim to compare the effects of preventative versus on demand nutritional advice in combination with nutritional support on reduction of weight loss in patients receiving standard antiviral therapy with PEG-interferon in combination with ribavirin. We will randomize patients for the preventative intervention with dietary consultation combined with dietary supplementation of a daily snack or the on demand dietary support group (only dietary follow up, no dietary advice or snack, standard care). In the on demand group, patients will be referred to the dietitian in case of weight loss of ≥ 5% or a BMI < 20 during antiviral therapy. Assuming that 60% reduction of weight loss during the first 24 weeks of treatment is clinically relevant, 2 x 25 patients need to be included (α=0.05, β=0.2: power=0.8 and a drop-out rate of 15%). Primary aim is to assess whether the intervention can decrease the amount of weight loss during therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of hepatitis C
  • •Indication for antiviral therapy
  • •Age > 18 years
  • •Good understanding of Dutch or English language
  • •Informed consent

排除标准

  • •Co-infection with hepatitis B and/or HIV
  • •Significant non hepatic diseases
  • •Significant previous surgery of the gastro-intestinal tract
  • •Hepatocellular carcinoma or other current malignant disease
  • •BMI < 20

研究组 & 干预措施

nutritional advise/support

Active Comparator

Nutritional advise and support

干预措施: Nutrison (Nutricia) (Dietary Supplement)

control

No Intervention

Control

结局指标

主要结局

Weight loss

时间窗: 1 year

次要结局

未报告次要终点

研究者

发起方
UMC Utrecht
申办方类型
Other

研究点 (1)

Loading locations...

相似试验